Shield Therapeutics (LON:STX) Shares Up 13% - Still a Buy?

Key Points

• Shield Therapeutics' shares surged 13% on Wednesday, reaching a high of GBX 5.30 before closing at GBX 5.20, with trading volume increasing by 165% compared to the average.
• The company has a market capitalization of £51.32 million and a notably high debt-to-equity ratio of 3,691.50, indicating significant leverage.
• Shield Therapeutics is focused on addressing iron deficiency with its product Accrufer®/Feraccru®, which has been launched in the U.S. to meet a substantial medical need.

Shield Therapeutics plc (LON:STX - Get Free Report)'s stock price traded up 13% on Wednesday . The stock traded as high as GBX 5.30 ($0.07) and last traded at GBX 5.20 ($0.07). 5,593,089 shares were traded during trading, an increase of 165% from the average session volume of 2,108,223 shares. The stock had previously closed at GBX 4.60 ($0.06).

Shield Therapeutics Price Performance

The company has a market cap of £60.69 million, a price-to-earnings ratio of -1.58 and a beta of 1.42. The company has a fifty day moving average price of GBX 3.56 and a two-hundred day moving average price of GBX 3.10. The company has a current ratio of 1.05, a quick ratio of 2.16 and a debt-to-equity ratio of 3,691.50.

Shield Therapeutics Company Profile

Shield is a commercial-stage specialty pharmaceutical company that delivers Accrufer®/Feraccru® (ferric maltol), an innovative and differentiated pharmaceutical product, to address a significant unmet need for patients suffering from iron deficiency, with or without anemia. The Company has launched Accrufer® in the U.S.